Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline. The company’s strategy centers on first-in-class therapies for diseases with high unmet medical need, leveraging a robust research platform to drive next-generation drug discovery in biotechnology.Kymera Theraputics develops novel small molecule therapeutics that target and degrade disease-causing proteins, with key programs in immunology, inflammation, hematologic mali ...